Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts

IMMUNIC, INC.

Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.
Bonney brings 30+ years biopharma experience, including Avonex launch at Biogen and CEO of Cubist (acquired by Merck for $9.5B).
Board size increased from 9 to 10; Bonney received option grant for 100k shares vesting over 3 years.
Company advances vidofludimus calcium toward phase 3 ENSURE readout in relapsing MS and planned PPMS program.
Simona Skerjanec remains as board member after transitioning from Interim Chair.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Simona Skerjanec

Member of the Board

IMUX · IMMUNIC, INC.

Effective: 2026-05-16
Successor: Michael W. Bonney
Filed: May 19, 2026, 7:00 AM ET

Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.

Appointed

Michael W. Bonney

Chair of the Board

IMUX · IMMUNIC, INC.

Effective: 2026-05-16
Filed: May 19, 2026, 7:00 AM ET

appointed Michael W. Bonney as Chair of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Simona Skerjanec changed role as Member of the Board at IMMUNIC, INC..

Action: transitioned from Interim Chairperson
Role: Member of the Board

Exact text from the filing

Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael W. Bonney was appointed as Chair of the Board at IMMUNIC, INC..

Action: appointed
Role: Chair of the Board

Exact text from the filing

appointed Michael W. Bonney as Chair of the Board, effective immediately.

View on SEC.gov

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-26-000645

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.